Figure 5 shows that since 2011, we aimed to decrease the cost of awareness (social events, material) in favour of testing (HIV testing, VL, CD4, hepatitis B vaccination, other screening tests) and ART. This evidence concerns the gene MLC1 and hepatitis B virus infection.